These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19949007)

  • 1. Adjuvant interferon in high-risk melanoma: end of the era?
    Janku F; Kurzrock R
    J Clin Oncol; 2010 Jan; 28(2):e15-6; author reply e17-8. PubMed ID: 19949007
    [No Abstract]   [Full Text] [Related]  

  • 2. Peginterferon alph-2b (Sylatron) for melanoma.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
    Mohr P; Hauschild A; Trefzer U; Weichenthal M
    J Clin Oncol; 2009 Aug; 27(24):e70; author reply e71. PubMed ID: 19620476
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
    Sondak VK; Flaherty LE
    Lancet; 2008 Jul; 372(9633):89-90. PubMed ID: 18620932
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
    Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
    Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
    Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
    Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Lawson BO; Khong HT
    Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 11. Thyrotoxicosis with pegylated interferon alfa-2b.
    Lowndes SA; Asher R; Middleton MR
    Arch Dermatol; 2010 Nov; 146(11):1273-5. PubMed ID: 21079065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 13. [Neck pain and fever after peginterferon alpha-2a].
    Moser C; Furrer J; Ruggieri F
    Praxis (Bern 1994); 2007 Feb; 96(6):205-7. PubMed ID: 17330412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of adjuvant interferon in high risk melanoma patients.
    Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
    [No Abstract]   [Full Text] [Related]  

  • 15. Cognitive function and quality of life in interferon therapy for melanoma.
    Bender CM; Yasko JM; Kirkwood JM; Ryan C; Dunbar-Jacob J; Zullo T
    Clin Nurs Res; 2000 Aug; 9(3):352-63. PubMed ID: 11276624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
    Helbig D; Simon JC; Treudler R
    Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
    [No Abstract]   [Full Text] [Related]  

  • 17. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?
    Radny P; Bauer J; Caroli UM; Eigentler TK; Kamin A; Metzler G; Garbe C
    Dermatology; 2004; 209(3):249-50. PubMed ID: 15459547
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant interferon in the treatment of melanoma.
    Kirkwood JM
    Br J Cancer; 2000 May; 82(10):1755-6. PubMed ID: 10817514
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon as adjuvant treatment for melanoma.
    Wheatley K; Ives N; Hancock B; Gore M
    Lancet; 2002 Sep; 360(9336):878. PubMed ID: 12243953
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.